Simpletouch Robotics Files for Hong Kong IPO Following $10M+ Series A+ Round Led by Walden International

Recently, surgical robotics company Shanghai Simpletouch Technology Co., Ltd. (hereinafter referred to as “Simpletouch Technology”) announced the completion of its tens-of-millions-level Series A+ financing round,Exclusively invested by Walden International, with Xilin Investment serving as the long-term exclusive financial advisor and the financial advisor for this round of transaction.This round of funding will be used for the NMPA registration and certification of its surgical robot products, market development and brand building, as well as the continuous R&D of multi-pipeline products. Simpletouch has completed two consecutive rounds of financing within just half a year in 2022, despite the pandemic.

Simpletouch, established just three years ago, has seen rapid progress with several of its products. Its tumor puncture surgical robot is on the verge of completing clinical trials and is about to initiate the registration process with the National Medical Products Administration (NMPA). The puncture surgical robot has undergone extensive clinical validation in hospitals in Shanghai, Anhui, and other regions. Simpletouch’s puncture surgical robot provides a more precise, efficient, and safe therapeutic approach for diverse and complex surgical scenarios, including puncture biopsy and tumor ablation. Meanwhile, leveraging its robotic platform R&D system, the company has also developed a series of products such as vascular intervention robots and laparoscopic robots, all of which represent significant technological advancements and supplements to current surgical treatment methods.

Huadeng International stated, “Simpletouch’s biopsy robot products feature technological originality, with their precision and efficiency already demonstrated in the clinical procedure of pulmonary nodule biopsy. We believe the company can leverage this technology platform to develop additional medical device products. Led by Dr. Liu Jian, the team boasts strong R&D capabilities and execution power. We are pleased to partner with the company and become an institutional shareholder of Simpletouch. We are confident that Simpletouch’s medical robotic products will not only serve domestic healthcare institutions and patients but also expand globally to support doctors and patients overseas.”

Mr. Wen Tianli, Founder and Chairman of Xilin Investment, stated, “Only a few months have passed since the Series A financing, yet Simpletouch Technology has swiftly secured tens of millions in Series A+ funding. We are honored that Xilin Investment has participated once again. In recent months, there have been numerous listings of large-scale medical device projects. As intelligent and networked medical devices are experiencing a significant surge, the substitution of imported products with domestically produced ones is imminent. We look forward to hearing more good news from Simpletouch Technology regarding product development and capital market achievements in the near future.”Yan Xiaolong, Head of the Healthcare Group at Xilin Investment and lead for this transaction, commented, “The Simpletouch Technology team demonstrates exceptional R&D innovation capabilities and strong product commercialization skills. By addressing patients’ medical needs while closely aligning with clinicians’ treatment practices, their products have gained high recognition from both patients and doctors. This will lay a solid foundation for the success of Simpletouch’s surgical robot products.”

Walden International Investment Group (hereinafter referred to as “Walden Group”) is an international venture capital firm founded in 1987 and is one of the most renowned venture capital institutions in the Asia-Pacific region. It currently manages funds exceeding USD 2 billion.

Xilin Investment, an elite boutique investment bank under Blue Lotus Capital Advisors, focuses primarily on the healthcare and technology sectors. Since its establishment in December 2014, it has facilitated financing totaling over RMB 4 billion for more than 30 projects. Xilin Investment maintains offices in Shenzhen, Shanghai, and Hong Kong.